Dare Bioscience DARE
NASDAQ DARE
$0.68 -0.01 (-1.26%)
As of: Oct 21, 2026 · 3:49 PM EDT

Dare Bioscience (DARE) Current Deferred Revenue (2016 - 2023)

Updated

Dare Bioscience (DARE) recorded Current Deferred Revenue of $205,206 in Q3 2023.

Analysis

Dare Bioscience (DARE) Current Deferred Revenue (2016 - 2023) Analysis & Trends

At the end of FY2016, Dare Bioscience reported Current Deferred Revenue of $2.5 million.

  • The Q3 2023 figure is the highest quarterly Current Deferred Revenue since Q2 2017.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 Dare Bioscience 10.13 Mn -55.33 Mn -132,343.00
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2023 205,206.00
Jun 30, 2017 2.50 Mn
Mar 31, 2017 2.50 Mn
Dec 31, 2016 2.50 Mn
API Access

Dare Bioscience Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=DARE&period=max&api_key=YOUR_API_KEY